tiprankstipranks

CymaBay downgraded to Market Perform from Strong Buy at Raymond James

Raymond James analyst Steven Seedhouse downgraded CymaBay Therapeutics (CBAY) to Market Perform from Strong Buy without a price target following the announcement of its proposed acquisition by Gilead (GILD) for $32.50 per share.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CBAY:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue